Eli Lilly and Company
Eli Lilly and Company LLY Peers
See (LLY) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LLY | $737.92 | +2.12% | 699.4B | 60.09 | $12.28 | +0.75% |
| AZN | $72.83 | +2.77% | 451.6B | 29.37 | $2.48 | +2.11% |
| JNJ | $154.96 | +0.90% | 372.8B | 17.26 | $8.98 | +3.23% |
| ABBV | $186.09 | +0.25% | 328.7B | 79.53 | $2.34 | +3.43% |
| NVO | $71.49 | +2.92% | 315.4B | 20.03 | $3.57 | +2.26% |
| NVS | $115.75 | +2.82% | 228.6B | 18.14 | $6.38 | +3.45% |
| MRK | $76.82 | +0.55% | 192.9B | 11.17 | $6.88 | +4.08% |
| AMGN | $287.80 | +1.50% | 154.8B | 26.24 | $10.97 | +3.22% |
| GILD | $110.08 | -0.93% | 136.9B | 14.22 | $7.74 | +2.81% |
| PFE | $23.47 | +0.06% | 133.4B | 17.00 | $1.38 | +7.21% |
Stock Comparison
LLY vs AZN Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, AZN has a market cap of 451.6B. Regarding current trading prices, LLY is priced at $737.92, while AZN trades at $72.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas AZN's P/E ratio is 29.37. In terms of profitability, LLY's ROE is +0.77%, compared to AZN's ROE of +0.19%. Regarding short-term risk, LLY is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs JNJ Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, JNJ has a market cap of 372.8B. Regarding current trading prices, LLY is priced at $737.92, while JNJ trades at $154.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas JNJ's P/E ratio is 17.26. In terms of profitability, LLY's ROE is +0.77%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, LLY is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs ABBV Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, ABBV has a market cap of 328.7B. Regarding current trading prices, LLY is priced at $737.92, while ABBV trades at $186.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas ABBV's P/E ratio is 79.53. In terms of profitability, LLY's ROE is +0.77%, compared to ABBV's ROE of +0.96%. Regarding short-term risk, LLY is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs NVO Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, NVO has a market cap of 315.4B. Regarding current trading prices, LLY is priced at $737.92, while NVO trades at $71.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas NVO's P/E ratio is 20.03. In terms of profitability, LLY's ROE is +0.77%, compared to NVO's ROE of +0.81%. Regarding short-term risk, LLY is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs NVS Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, NVS has a market cap of 228.6B. Regarding current trading prices, LLY is priced at $737.92, while NVS trades at $115.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas NVS's P/E ratio is 18.14. In terms of profitability, LLY's ROE is +0.77%, compared to NVS's ROE of +0.31%. Regarding short-term risk, LLY is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs MRK Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, MRK has a market cap of 192.9B. Regarding current trading prices, LLY is priced at $737.92, while MRK trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas MRK's P/E ratio is 11.17. In terms of profitability, LLY's ROE is +0.77%, compared to MRK's ROE of +0.38%. Regarding short-term risk, LLY is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs AMGN Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, AMGN has a market cap of 154.8B. Regarding current trading prices, LLY is priced at $737.92, while AMGN trades at $287.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas AMGN's P/E ratio is 26.24. In terms of profitability, LLY's ROE is +0.77%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, LLY is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs GILD Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, GILD has a market cap of 136.9B. Regarding current trading prices, LLY is priced at $737.92, while GILD trades at $110.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas GILD's P/E ratio is 14.22. In terms of profitability, LLY's ROE is +0.77%, compared to GILD's ROE of +0.32%. Regarding short-term risk, LLY is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs PFE Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, PFE has a market cap of 133.4B. Regarding current trading prices, LLY is priced at $737.92, while PFE trades at $23.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas PFE's P/E ratio is 17.00. In terms of profitability, LLY's ROE is +0.77%, compared to PFE's ROE of +0.09%. Regarding short-term risk, LLY is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs SNY Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, SNY has a market cap of 121.9B. Regarding current trading prices, LLY is priced at $737.92, while SNY trades at $49.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas SNY's P/E ratio is 17.51. In terms of profitability, LLY's ROE is +0.77%, compared to SNY's ROE of +0.08%. Regarding short-term risk, LLY is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs BMY Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, BMY has a market cap of 98.2B. Regarding current trading prices, LLY is priced at $737.92, while BMY trades at $48.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas BMY's P/E ratio is 18.01. In terms of profitability, LLY's ROE is +0.77%, compared to BMY's ROE of +0.32%. Regarding short-term risk, LLY is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs GSK Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, GSK has a market cap of 83.4B. Regarding current trading prices, LLY is priced at $737.92, while GSK trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas GSK's P/E ratio is 19.92. In terms of profitability, LLY's ROE is +0.77%, compared to GSK's ROE of +0.22%. Regarding short-term risk, LLY is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs CELG-RI Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, CELG-RI has a market cap of 78.4B. Regarding current trading prices, LLY is priced at $737.92, while CELG-RI trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, LLY's ROE is +0.77%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, LLY is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.
LLY vs HZNP Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, LLY is priced at $737.92, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas HZNP's P/E ratio is 61.86. In terms of profitability, LLY's ROE is +0.77%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, LLY is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs BIIB Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, BIIB has a market cap of 19B. Regarding current trading prices, LLY is priced at $737.92, while BIIB trades at $129.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas BIIB's P/E ratio is 12.31. In terms of profitability, LLY's ROE is +0.77%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, LLY is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs GRFS Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, LLY is priced at $737.92, while GRFS trades at $8.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas GRFS's P/E ratio is 31.96. In terms of profitability, LLY's ROE is +0.77%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, LLY is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs OGN Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, OGN has a market cap of 2.4B. Regarding current trading prices, LLY is priced at $737.92, while OGN trades at $9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas OGN's P/E ratio is 3.07. In terms of profitability, LLY's ROE is +0.77%, compared to OGN's ROE of +1.82%. Regarding short-term risk, LLY is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs CTOR Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, CTOR has a market cap of 64.4M. Regarding current trading prices, LLY is priced at $737.92, while CTOR trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas CTOR's P/E ratio is -2.37. In terms of profitability, LLY's ROE is +0.77%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, LLY is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.
LLY vs SCLXW Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, SCLXW has a market cap of 41.1M. Regarding current trading prices, LLY is priced at $737.92, while SCLXW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas SCLXW's P/E ratio is N/A. In terms of profitability, LLY's ROE is +0.77%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, LLY is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for LLY.
LLY vs SCLX Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, SCLX has a market cap of 35.7M. Regarding current trading prices, LLY is priced at $737.92, while SCLX trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas SCLX's P/E ratio is -0.34. In terms of profitability, LLY's ROE is +0.77%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, LLY is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.
LLY vs MIRA Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, MIRA has a market cap of 22.7M. Regarding current trading prices, LLY is priced at $737.92, while MIRA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas MIRA's P/E ratio is -2.85. In terms of profitability, LLY's ROE is +0.77%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, LLY is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.
LLY vs SRXH Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, SRXH has a market cap of 6.5M. Regarding current trading prices, LLY is priced at $737.92, while SRXH trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas SRXH's P/E ratio is N/A. In terms of profitability, LLY's ROE is +0.77%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, LLY is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.
LLY vs CRXT Comparison
LLY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LLY stands at 699.4B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, LLY is priced at $737.92, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LLY currently has a P/E ratio of 60.09, whereas CRXT's P/E ratio is -0.02. In terms of profitability, LLY's ROE is +0.77%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, LLY is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for LLY.